Status:

COMPLETED

Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD

Lead Sponsor:

University Health Network, Toronto

Conditions:

Age Related Macular Degeneration

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this study is to evaluate the level of cytokines (which are small proteins important in cell signalling) in eye fluid (aqueous humour) in patients with wet age related macular degenerat...

Detailed Description

In the treatment of CNV (Choroidal NeoVascularization) secondary from AMD (Age Related Macular Degeneration) by using ranibizumab, patients who are non-responders can be found in approximately 1-10% o...

Eligibility Criteria

Inclusion

  • Age 50 years or more
  • Ranibizumab resistance/poor responder patients in all AMD entities (typical AMD, PCV and RAP) who will be treated with intravitreous ranibizumab in combination with verteporfin photodynamic therapy
  • Ranibizumab resistance/poor responder patients in all AMD entity (typical AMD, PCV and RAP) who will be treated with intravitreous aflibercept injection
  • AMD patient who is good response to the treatment of ranibizumab (control group)

Exclusion

  • Any evidence of good response in treatment of ranibizumab,
  • Uncooperative patients to intravitreal treatment
  • Patients who have clinically active ocular inflammation
  • Patients who have previous PDT treatment within 6 months
  • Patient who previously have ocular treatment of immunosuppressive agent within 3 months
  • Patient who previously have ocular treatment of steroid with in 3 months
  • Patients who are currently on systemic treatment of anti-VEGF medication or immunosuppressive agents.

Key Trial Info

Start Date :

August 1 2014

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 1 2016

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT02218177

Start Date

August 1 2014

End Date

December 1 2016

Last Update

October 11 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Toronto Western Hospital

Toronto, Ontario, Canada, M2N4H3

Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD | DecenTrialz